-+ 0.00%
-+ 0.00%
-+ 0.00%

Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026

PUBT·05/28/2026 21:02:17
Listen to the news
Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026
  • Allogene Therapeutics outlined a CEO succession, with David Chang stepping down as president and CEO effective June 30, 2026.
  • Chang will remain on the board.
  • Zachary Roberts, EVP of R&D and chief medical officer, becomes president and CEO effective July 1, 2026.
  • Roberts will join the board on July 1, 2026.
  • Roberts previously held leadership roles at Instil Bio and Kite Pharma, focused on CAR T development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605281702PRIMZONEFULLFEED9728357) on May 28, 2026, and is solely responsible for the information contained therein.